Tumor Cell “Slimming” Regulates Tumor Progression through PLCL1/UCP1‐Mediated Lipid Browning

Zhang, Xiong; Xiao, Wen; Bao, Lin; Xiong, Wei; Xiao, Heng; Qü, Yan; Yuan, Chunrong; Ruan, Hailong; Cao, Qi; Wang, Keshan; Song, Zhengshuai; Wang, Cheng; Hu, Wenjun; Ru, Zeyuan; Tong, Junwei; Chen, Gong; Xu, Tianbo; Meng, Xiang‐Gao; Shi, Jian; Chen, Zhixian; Yang, Hongmei; Chen, Ke; Zhang, Xiaoping

doi:10.1002/advs.201801862

Cited by 37 publications

(45 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies have found that increased levels of Stearoyl-CoA desaturase 1 and fatty acid synthase in KIRC tissues are required for tumor growth and progression [74, 75]. In addition, a recent study has found that phospholipase C-like 1/uncoupling protein 1 mediating lipid browning could promote kidney cancer cell “slimming” and consume abnormal lipid accumulation, which represses the progression of ccRCC [76]. Reductive carboxylation was also involved in the progression of RCC [58, 77–80].…”

Section: Discussionmentioning

confidence: 99%

A cluster of long non-coding RNAs exhibit diagnostic and prognostic values in renal cell carcinoma

Chen

Liu

Liang

et al. 2019

Aging

Self Cite

View full text Add to dashboard Cite

Kidney cancer ranked in the top 10 for both men and women in the estimated numbers of new cancer cases in the United States in 2018. Targeted therapies have recently been administered to patients with clear cell renal cell carcinoma (ccRCC), but the overall survival of patients at the terminal stage of the disease has not been as good as expected. It is therefore necessary to uncover efficient biomarkers for early diagnosis, and to clarify the molecular mechanisms underlying ccRCC progression and metastasis. Increased evidence has shown that long non-coding RNAs (lncRNAs) play important roles during tumor progression. In this study, 10 candidate lncRNAs with diagnostic and prognostic values in ccRCC were identified: IGFL2-AS1, AC023043.1, AP000439.2, AC124854.1, AL355102.4, TMEM246-AS1, AL133467.3, ZNF582-AS1, LINC01510 and PSMG3-AS1. Enrichment analysis revealed metabolic and functional pathways, which may be closely associated with kidney cancer tumorigenesis. Six representative processes were summarized, namely glycolysis, amino acid metabolism, lipid synthesis, reductive carboxylation, nucleotide metabolism, transmembrane transport and signal transduction. In combination, the present results provided prognostic and diagnostic biomarkers for ccRCC and might pave the way for targeted intervention and molecular therapies in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

A cluster of long non-coding RNAs exhibit diagnostic and prognostic values in renal cell carcinoma

Chen

Liu

Liang

et al. 2019

Aging

Self Cite

View full text Add to dashboard Cite

show abstract

“…PLCL1 is downregulated in clear cell renal carcinoma (ccRCC) and predicted a poor prognosis. Restoration of PLCL1 expression in ccRCC cells repressed tumor progression, reduced abnormal lipid accumulation, and caused tumor cell "slimming" through UCP1-mediated lipid browning, which consumes lipids without producing ATP energy [61].…”

Section: Serbp1 As a New Regulator Of Cancer Metabolismmentioning

confidence: 99%

The RNA-binding protein SERBP1 functions as a novel oncogenic factor in glioblastoma by bridging cancer metabolism and epigenetic regulation

Kosti

Araújo

et al. 2020

Genome Biol

View full text Add to dashboard Cite

Background: RNA-binding proteins (RBPs) function as master regulators of gene expression. Alterations in RBP expression and function are often observed in cancer and influence critical pathways implicated in tumor initiation and growth. Identification and characterization of oncogenic RBPs and their regulatory networks provide new opportunities for targeted therapy. Results: We identify the RNA-binding protein SERBP1 as a novel regulator of glioblastoma (GBM) development. High SERBP1 expression is prevalent in GBMs and correlates with poor patient survival and poor response to chemo-and radiotherapy. SERBP1 knockdown causes delay in tumor growth and impacts cancer-relevant phenotypes in GBM and glioma stem cell lines. RNAcompete identifies a GC-rich region as SERBP1-binding motif; subsequent genomic and functional analyses establish SERBP1 regulation role in metabolic routes preferentially used by cancer cells. An important consequence of these functions is SERBP1 impact on methionine production. SERBP1 knockdown decreases methionine levels causing a subsequent reduction in histone methylation as shown for H3K27me3 and upregulation of genes associated with neurogenesis, neuronal differentiation, and function. Further analysis demonstrates that several of these genes are downregulated in GBM, potentially through epigenetic silencing as indicated by the presence of H3K27me3 sites. Conclusions: SERBP1 is the first example of an RNA-binding protein functioning as a central regulator of cancer metabolism and indirect modulator of epigenetic regulation in GBM. By bridging these two processes, SERBP1 enhances glioma stem cell phenotypes and contributes to GBM poorly differentiated state.

show abstract

“…RNA oligonucleotides were obtained from RiboBio (Guangzhou, China) as previous research. 22 Forty-eight hours later, the cells were prepared for further analysis.…”

Section: Rna Extraction and Qrt-pcrmentioning

confidence: 99%

<p>MiR-935 Promotes Clear Cell Renal Cell Carcinoma Migration and Invasion by Targeting IREB2</p>

Liu

Chen

et al. 2019

CMAR

View full text Add to dashboard Cite

Purpose: Clear cell renal cell carcinoma (ccRCC) has the highest rate of metastasis and invasion in RCC and is the third most common adult urinary malignancy. miRNA may serve a critical role in human cancer development and progression, has been confirmed to play a pivotal role in RCC cell invasion and migration. Since miR-935 had been verified to be an oncogene or tumor suppressor in various cancers, the role of miR-935 in RCC was unclear. Methods: Real-time quantitative polymerase chain reaction (qRT-PCR) was used to verify miR-935 expression. CCK-8 assay, wound healing assay and transwell assay were used to investigate the cell proliferation, migration and invasion of miR-935. Receiver operating characteristic (ROC) curve analysis was applied to discriminate different clinical classifications. Gain or loss of function approaches were used to investigate the cell proliferation, migration and invasion of miR-935 in vitro. Bioinformatics analysis and dual-luciferase reporter assay were used to identify the target of miR-935. Results: MiR-935 had a higher expression level in RCC cells and cancer tissues. MiR-935 mimics promoted cell proliferation, migration and invasion, and miR-935 inhibitor inhibited cell inhibit malignancy of cancer cells. Bioinformatics analysis and dual-luciferase reporter assay identified iron-responsive element-binding protein 2 (IREB2) as a direct target of miR-935. qRT-PCR showed IREB2 expression was downregulated in ccRCC cancer tissues and high IREB2 expression had a longer overall survival (OS) and disease-free survival (DFS). Silencing IREB2 could reverse the function of miR-935 inhibitor on cell proliferation and metastasis in renal cancer cells. Conclusion: The study indicated that miR-935 may act as an oncomiRNA and influenced migration and invasion progress of ccRCC by targeting IREB2. Oncogene miR-935 may be a molecular marker and uncover new strategies for ccRCC.

show abstract

Tumor Cell “Slimming” Regulates Tumor Progression through PLCL1/UCP1‐Mediated Lipid Browning

Cited by 37 publications

References 47 publications

A cluster of long non-coding RNAs exhibit diagnostic and prognostic values in renal cell carcinoma

A cluster of long non-coding RNAs exhibit diagnostic and prognostic values in renal cell carcinoma

The RNA-binding protein SERBP1 functions as a novel oncogenic factor in glioblastoma by bridging cancer metabolism and epigenetic regulation

<p>MiR-935 Promotes Clear Cell Renal Cell Carcinoma Migration and Invasion by Targeting IREB2</p>

Contact Info

Product

Resources

About